Buspar (buspirone) is not a mood stabilizer. It is classified as an anxiolytic, meaning it is FDA-approved specifically for treating anxiety. It does not meet the clinical criteria for a mood stabilizer and is not recommended as one in any major psychiatric treatment guideline.
How Buspirone Is Classified
Buspirone belongs to a class of medications called azapirones. The FDA approved it for one indication: the treatment of anxiety disorders. It works differently from benzodiazepines (like Xanax or Ativan) and differently from mood stabilizers. Its primary action is as a partial agonist at a specific serotonin receptor, meaning it partially activates certain serotonin pathways in the brain rather than fully turning them on or off. Over time, this modulates how serotonin signals are sent and received, which gradually reduces anxiety symptoms.
The typical starting dose is 7.5 mg twice daily, with a maximum of 60 mg per day. Unlike benzodiazepines, buspirone takes one to two weeks to reach its full effect and does not cause sedation or carry a risk of physical dependence.
What Makes a Drug a Mood Stabilizer
The term “mood stabilizer” is surprisingly informal. The FDA does not officially recognize the category, and psychiatrists have no universally agreed-upon definition. The most widely cited framework, published in the American Journal of Psychiatry, proposes that a true mood stabilizer should do four things: treat acute mania, treat acute depression, prevent future manic episodes, and prevent future depressive episodes. Lithium and certain anticonvulsants (like valproate and lamotrigine) are the drugs most commonly placed in this category, along with some atypical antipsychotics.
Buspirone has no demonstrated ability to do any of these four things reliably. It does not treat or prevent mania. It does not treat or prevent depressive episodes. Its mechanism of action targets anxiety-related serotonin pathways, not the broader mood cycling seen in conditions like bipolar disorder.
Why People Confuse the Two
The confusion likely comes from the overlap between anxiety and mood symptoms. When anxiety improves, people often feel more emotionally stable, sleep better, and find their overall mood more even. That can feel like mood stabilization, but it’s a secondary benefit of anxiety relief, not a direct effect on mood cycling.
Buspirone is also sometimes prescribed alongside antidepressants as an augmentation strategy, which can create the impression that it plays a role in mood management. Clinicians occasionally add buspirone to an SSRI regimen for patients who haven’t fully responded to the antidepressant alone, particularly when residual anxiety is part of the picture. However, the evidence for this approach is mixed. Two double-blind, placebo-controlled trials of buspirone added to SSRIs in treatment-resistant depression failed to show a significant benefit over placebo. A post-hoc analysis from one of those trials suggested a possible benefit in patients with severe depression, but that kind of after-the-fact finding is considered preliminary, not conclusive. In head-to-head comparisons, bupropion augmentation produced roughly double the remission rate of buspirone augmentation (18% versus 9%).
Buspirone and Bipolar Disorder
If you have bipolar disorder, the question of whether buspirone is a mood stabilizer becomes especially important. One set of international treatment guidelines (the Korean Medication Algorithm Project, 2022) lists buspirone as a third-line adjunctive option for bipolar depression, meaning it is far down the list of preferred treatments and would only be considered after first and second-line options have failed.
There is also a documented risk that buspirone can trigger mania or hypomania in people with bipolar disorder. Case reports in the American Journal of Psychiatry describe patients with bipolar disorder who developed manic symptoms within weeks of starting buspirone. In one case, a woman who had been stable and medication-free for two years became hypomanic after four weeks on buspirone, with elevated mood, pressured speech, and racing thoughts. While any single case could be coincidental, the pattern is consistent with what clinicians see with other serotonin-active medications in bipolar patients.
This is the opposite of what a mood stabilizer does. A mood stabilizer prevents manic episodes. A drug that can potentially trigger them is, by definition, not stabilizing mood in the way that term is used clinically.
What Buspirone Actually Does Well
Buspirone is effective for what it was designed to treat: generalized anxiety. It reduces worry, tension, and the physical symptoms of chronic anxiety without the sedation, cognitive dulling, or dependence risk that comes with benzodiazepines. It takes longer to work, which can be frustrating, but for people who need long-term anxiety management it offers a safer profile.
Its side effects are generally mild. Common ones include dizziness, nausea, and headache. It does not impair coordination or reaction time the way sedating anti-anxiety drugs do, and stopping it does not cause withdrawal symptoms. For people whose mood instability is actually driven by untreated anxiety, buspirone can make a meaningful difference in how they feel day to day, even though it is not acting as a mood stabilizer in the clinical sense.
If you’re looking for true mood stabilization, particularly for bipolar disorder or significant mood swings, that conversation involves a different class of medications entirely. Lithium, anticonvulsants like valproate and lamotrigine, and certain atypical antipsychotics are the drugs with evidence for that purpose.